Human milk oligosaccharides against later in life excessive fat mass accumulation and related health disorders
The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in an infant or a young child for reducing and/or preventing later in life excessive fat mass accumulation and/or a health disorder related to excessive fat mass accumulation, wherein said fucosylated oligosaccharide has at least one fucose group attached by an alpha 1,3 linkage, at least one fucose group attached by an alpha 1,4 linkage, or combinations thereof. The invention also relates to nutritional composition for use to promote healthy growth.
1. A method for reducing and/or avoiding excessive fat mass accumulation and/or a health disorder related to the excessive fat mass accumulation in an infant or young child later in life, the method comprising administering a nutritional composition comprising at least one fucosylated oligosaccharide to the infant or young child, wherein the at least one fucosylated oligosaccharide has at least one fucose group attached by an alpha 1,3 linkage, at least one fucose group attached by an alpha 1,4 linkage, or combinations thereof,
wherein the at least one fucosylated oligosaccharide comprises diFucosyllactose (DFL) in an amount of 0.02-2.78 g/100 g of the nutritional composition on a dry weight basis, and the infant or young child is born to a mother carrying SNP rs3894326.
2. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide has been fucosylated by Fucosyltransferase 3 (FUT3).
3. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide further comprises an additional fucosylated oligosaccharide selected from the group consisting of 3′ fucosylated lactose (3FL), Lacto-N-fucopentaose II (LNFP II), Lacto-N-fucopentaose III (LNFP III), Lacto-N-fucopentaose V (LNFP V), and combinations thereof.
4. The method according to claim 3 , wherein the additional fucosylated oligosaccharide comprises 3′ fucosylated lactose.
5. The method according to claim 1 , wherein the health disorder related to the excessive fat mass accumulation is selected from the group consisting of overweight, obesity, type 2 diabetes, insulin resistance, hypertension, cardiovascular disease, metabolic syndrome and premature adiposity rebound.
6. The method according to claim 1 , wherein the health disorder related to the excessive fat mass accumulation is premature adiposity rebound.
7. The method according to claim 1 , wherein the nutritional composition has a formulation selected from the group consisting of (i) the at least one fucosylated oligosaccharide consists of the DFL and (ii) the at least one fucosylated oligosaccharide consists of the DFL and at least one of another 1,2 fucosylated lactose or 2 fucosylated lactose.
8. The method according to claim 1 , wherein the nutritional composition further comprises at least one further oligosaccharide(s) and/or fiber(s) and/or precursor(s) of human milk oligosaccharide selected from the group consisting of galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), xylo-oligosaccharides (XOS), inulin, polydextrose, sialylated oligosaccharides, sialic acid, fucose, N-acetylated oligosaccharides and combinations thereof.
9. The method according to claim 1 , wherein the nutritional composition comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of the nutritional composition on a dry weight basis.
10. The method according to claim 1 , wherein the nutritional composition is not a breast milk and is a synthetic nutritional composition in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a growing up milk, a fortifier and a supplement.
11. The method according to claim 1 , wherein the nutritional composition is administered in an amount effective to prevent premature adiposity rebound.